Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.30
$7.17
52-Week Range
N/A
Volume
137,800 shs
Average Volume
103,866 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Remembering John Harlin, Eiger Legend
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Eiger Biopharmaceuticals Inc (EIGRQ)
Massive Rockfall on the North Face of the Eiger
Eiger BioPharmaceuticals, Inc. (EIGRQ)
72C.SG,0P00015QPW,0 (72C.SG)
See More Headlines

EIGR Stock Analysis - Frequently Asked Questions

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($17.40) by $2.10. The biotechnology company earned $3.04 million during the quarter, compared to analyst estimates of $2.54 million. Eiger BioPharmaceuticals had a negative net margin of 590.80% and a negative trailing twelve-month return on equity of 332.49%.

Eiger BioPharmaceuticals's stock reverse split on the morning of Monday, January 8th 2024.The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA).

Company Calendar

Last Earnings
11/04/2021
Today
7/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EIGR
Employees
56
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$96.78 million
Net Margins
-590.80%
Pretax Margin
-590.79%

Debt

Sales & Book Value

Annual Sales
$15.77 million
Price / Cash Flow
N/A
Book Value
$37.68 per share
Price / Book
N/A

Miscellaneous

Free Float
1,419,000
Market Cap
$2.55 million
Optionable
Optionable
Beta
1.83

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:EIGR) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners